Home » EPIGENOMICS AG ANNOUNCES CONTINUATION OF PHARMACEUTICAL BIOMARKER RESEARCH COLLABORATION
EPIGENOMICS AG ANNOUNCES CONTINUATION OF PHARMACEUTICAL BIOMARKER RESEARCH COLLABORATION
Epigenomics AG, a molecular diagnostics company developing tests based on DNA methylation, announced today that the company has entered into an agreement to continue a collaboration with AstraZeneca Ltd. to identify and analyse potential DNA methylation biomarker candidates for use in AstraZeneca's oncology programs.
The Houston Chronicle (http://www.chron.com/disp/story.mpl/conws/3866430.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May